RxDoctor Payments Data

Safwat Gassis, MD

Clinical Cardiac Electrophysiology · Camp Hill, PANPI 1891755922

Payments from drug & device makers

$14,783in general payments, 2019–2025

Across 59 payments — averaging $250.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$10K
  • Boston Scientific$2K
  • Medtronic$2K
  • Atricure, Inc.$905
  • Johnson & Johnson$328
  • Cardiva Medical, Inc.$39
  • plus $45 from 2 others

What the payments were for

  • Travel & lodging$1,36429%
  • Food & beverage$3,28071%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Abbott6$10,171
Boston Scientific18$1,679
Medtronic(2 entities)15$1,616
Atricure, Inc.13$905
Johnson & Johnson3$328
Cardiva Medical, Inc.2$39
Bardy Diagnostics, Inc.1$32
Impulse Dynamics (USA) Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,783 in reported general payments places this provider in the 35th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

See all clinical cardiac electrophysiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$148,015
Medicare patients
805
Services billed
1,631

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban98$103,375
XareltoRivaroxaban38$42,786
Propafenone Hcl ErPropafenone Hcl12$3,740
Metoprolol Succinate135$2,453
Flecainide Acetate55$2,224
Propafenone Hcl34$1,578
Amiodarone Hcl64$663
Warfarin Sodium38$604
Diltiazem 24hr Er (Cd)Diltiazem Hcl17$476
Metoprolol Tartrate34$381
Atorvastatin Calcium24$256
Amlodipine Besylate30$191
Furosemide26$163
Losartan Potassium13$148
Verapamil SrVerapamil Hcl17$103

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$328$42,78638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 201 clinical cardiac electrophysiology providers in Pennsylvania.

Other clinical cardiac electrophysiology in Camp Hill

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →